

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 661  
**Publication Number:** P400

**Abstract Group:** 1.13. Clinical Problems - Other

**Keyword 1:** Interstitial lung disease **Keyword 2:** Treatments **Keyword 3:** Chronic disease

**Title:** Administration of lasolvan in the treatment for exogenic allergic alveolitis (EAA)

Dr. Natalya 5452 Makaryants roman4000@yandex.ru MD <sup>1</sup>, Prof. Larisa 5453 Lepekha roman4000@yandex.ru <sup>1</sup>, Prof. Dr Eugene 5454 Shmelev roman4000@yandex.ru MD <sup>1</sup> and Dr. Ilya 5455 Sivokozov grand63@yandex.ru MD <sup>1</sup>. <sup>1</sup> Respiratory/Pathology Department, CTRI RAMS, Moscow, Russian Federation .

**Body:** Aim: To evaluate efficacy of continuous treatment for subacute variant of EAA with inhalation lasolvan. Materials and methods: We studied 27 patients with subacute course of morphologically confirmed EAA. Group 1 (10 patients) received the standard treatment with prednisolone (20 mg/day). Group 2 (17 patients) received prednisolone (15 mg/day) plus inhalation lasolvan. We evaluated clinical symptoms (cumulative index), 6-minute walk test, spirometry, diffusing capacity of the lung (DLCO), computed tomography (CT) of the lungs using Kazerooni modification, before and after the treatment. The reliability of differences was estimated using the Wilcoxon test. Results: There were no reliable differences between the groups. The analysis of the data within the both groups revealed reliable improvement of clinical symptoms, LVC, distances of the 6-minute walk test, the alveolar component of CT. In group 2 we also observed increased DLCO.

Parameter	Prednisolone		Prednisolone + Lasolvan	
	Before treatment	After treatment	Before treatment	After treatment
	M±m	M±m	M±m	M±m
Cumulative index	2.46±0.24	1.42±0.15*	2.86±0.23	1.37±0.23*525.00±15.76*
6 MWT	456.54±14.55	504.25±19.10*	470.00±13.55	525.00±15.76*
LVC	87.21±5.48	92.00±4.43*	91.45±2.87	98.72±2.97*
FEV1	84.20±6.01	89.42±4.31	84.08±3.51	90.03±3.92
DLCO	65.83±4.95	65.83±5.43	63.93±3.41	68.76±3.18*
Chest CT (A)	3.15±0.27	2.00±0.37*	3.05±0.16	1.68±0.28*
Chest CT (I)	0.38±0.21	0.33±0.19	0.71±0.16	0.53±0.14

\*p<0.05

**Conclusion:** Nebulizer administration of lasolvan in the complex treatment for subacute course of EAA

allows decreasing corticosteroid doses.